Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multi-k...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biol Blood Marrow Transplant
Autores principales: Baird, Kristin, Comis, Leora E., Joe, Galen O., Steinberg, Seth M., Hakim, Fran T., Rose, Jeremy J., Mitchell, Sandra A., Pavletic, Steven Z., Figg, William D., Yao, Lawrence, Flanders, Kathleen C., Takebe, Naoko, Sarantopoulos, Stefanie, Booher, Susan, Cowen, Edward W.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425991/
https://ncbi.nlm.nih.gov/pubmed/25771402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.03.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares